Anti-human CD3e Monoclonal Antibody (Clone OKT3), Mouse IgG2a Kappa Ushelf

Anti Human CD3e Antibody, clone OKT3 | PA007202.m2a

$150.00 – $900.00

Recombinant rat IgG2a isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

Details & Specifications
References

Catalog No.	PA007202.m2a
Product Name	In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: OKT3), Mouse IgG2a Kappa
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	cluster of differentiation 3, CD3D, CD3E, CD3G
Summary	The anti-human CD3 monoclonal antibody (OKT3) was produced in mammalian cells.
Clone	OKT3
Isotype	Mouse IgG2a kappa
Specificity/Sensitivity	The in vivo grade recombinant anti-human CD3 antibody (Clone: OKT3) specifically binds to the human T cell receptor CD3.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD3 protein.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The in vivo grade recombinant anti-human CD3 monoclonal antibody, Mouse IgG2a Kappa (clone: OKT3) is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant mouse IgG2a isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007202.m2a: Recombinant Anti-human CD3 Monoclonal Antibody (Clone: OKT3), Mouse IgG2a Kappa, In vivo Grade

Background

The OKT3 antibody binds to CD3 epsilon of the T cell receptor-CD3 complex found only on mature T cells and medullary thymocytes. An interaction between T cells, OKT3, and monocytes causes T-cell activation (mitogenesis) in vitro. On the other hand, the OKT3 antibody blocks the unique association between the antigen receptor and CD3, and both the generation and function of cytotoxic T cells. After an initial dose of the OKT3 antibody, T cells disappear from the circulation within minutes to hours. During treatment with the OKT3 antibody, T cells bearing the usual array of surface molecules (CD2, CD4, and CD8) reappear in the peripheral blood circulation but these cells are devoid of CD3. After another 48 hours without the OKT3 antibody, the normal array of surface molecules including CD3 appear again on all T cells. The selective removal of CD3 by internalization is thought to be the key mechanism of action of the OKT3 antibody. Comodulation of the antigen receptor with CD3 explains the immunoblocking action of the OKT3 antibody in vivo. The OKT3 antibody is ineffective clinically if the CD3 target molecule is not modulated.

The OKT3 antibody is effective for induction of immunosuppression and for treating initial and steroid-resistant rejections.

References of Anti-Human CD3 Monoclonal Antibody (Clone: OKT3)

1. Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model.
Julie A Zorn, et al. Sci Rep. 2022 Mar 3;12(1):3530. doi: 10.1038/s41598-022-06953-7. PMID: 35241687; PMCID: PMC8894342
“T-cell engagers (TCEs) are a growing class of biotherapeutics being investigated in the clinic for treatment of a variety of hematological and solid tumor indications. However, preclinical evaluation of TCEs in vivo has been mostly limited to xenograft tumor models in human T-cell reconstituted immunodeficient mice, which have a number of limitations…”

2. Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage.
Shihyoung Kim, et al. Toxins (Basel). 2022 Jun 15;14(6):410. doi: 10.3390/toxins14060410. PMID: 35740248; PMCID: PMC9220018
“Anti-CD3-epsilon (CD3e) monoclonal antibodies (mAbs) and CD3e immunotoxins (ITs) are promising targeted therapy options for various T-cell disorders. CD3e-ITs may induce vascular leak syndrome (VLS) via the CD3e binding portion of IT, that may induce an excessive activation of T cells, and the toxin portion that can directly damage vascular endothelial cells…”

3. TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy.
Rasmus O. Nielsen, et al. JCI Insight. 2018 Jul 12;3(13):e99442. doi: 10.1172/jci.insight.99442. PMID: 29997304; PMCID: PMC6124532
“T cells engineered to express chimeric antigen receptors (CARs) against B cell antigens are being investigated as cellular immunotherapies. Similar approaches designed to target T cell malignancies have been hampered by the critical issue of T-on-T cytotoxicity, whereby fratricide or self-destruction of healthy T cells prohibits cell product manufacture…”

4. A humanized CD3ε-knock-in mouse model for pre-clinical testing of anti-human CD3 therapy.
Paul S. Moore, et al. PLoS One. 2021 Feb 17;16(2):e0245917. doi: 10.1371/journal.pone.0245917. PMID: 33596227; PMCID: PMC7888618
“Pre-clinical murine models are critical for translating drug candidates from the bench to the bedside. In this study, we report a murine genetic knock-in model which expresses both a murine and a humanized-CD3ε-exon, rendering it sensitive to manipulation with anti-human CD3…”

5. Differential depletion of total T cells and regulatory T cells and prolonged allotransplant survival in CD3Ɛ humanized mice treated with polyclonal anti human thymocyte globulin.
Maja Buszko, et al. PLoS One. 2017 Mar 3;12(3):e0173088. doi: 10.1371/journal.pone.0173088. PMID: 28257450; PMCID: PMC5336254
“Thymoglobulin (ATG) is a polyclonal rabbit antibody against human thymocytes used as a T cell-depleting agent to prevent or treat allotransplant rejection. In the field of allotransplantation, another antibody-based immunosuppressive therapy specifically targets CD3 molecules, where the main effect of anti-CD3 monoclonal antibodies (mAbs) (OKT3) is T cell depletion…”